F
Francisco López-Muñoz
Researcher at Universidad Camilo José Cela
Publications - 317
Citations - 4484
Francisco López-Muñoz is an academic researcher from Universidad Camilo José Cela. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 293 publications receiving 3808 citations. Previous affiliations of Francisco López-Muñoz include Carlos III Health Institute & Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
TL;DR: The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuroscientific disciplines.
Journal ArticleDOI
History of the discovery and clinical introduction of chlorpromazine
Francisco López-Muñoz,Cecilio Alamo,Eduardo Cuenca,Winston W. Shen,Patrick Clervoy,Gabriel Rubio +5 more
TL;DR: The discovery of the antipsychotic properties of chlorpromazine in the 1950s was a fundamental event for the practice of psychiatry and for the genesis of the so-called "psychopharmacological revolution."
Journal Article
The history of barbiturates a century after their clinical introduction
TL;DR: The problems of safety which, accompanied by the introduction of a range of psychoactive drugs in the 1950s, brought an end to barbiturate use, except in specific applications, such as the induction of anesthesia and the treatment of certain types of epilepsy.
Journal ArticleDOI
Neuron theory, the cornerstone of neuroscience, on the centenary of the Nobel Prize award to Santiago Ramón y Cajal.
TL;DR: The present work makes a historical analysis of the circumstances in which Cajal formulated his theory, considering the authors and works that influenced his postulate, the difficulties he encountered for its dissemination, and the way it finally became established.
Journal ArticleDOI
Long-Acting Injectable Risperidone Compared with Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity
Gabriel Rubio,I. Martinez,Guillermo Ponce,Miguel Ángel Jiménez-Arriero,Francisco López-Muñoz,Cecilio Alamo +5 more
TL;DR: Long-acting injectable risperidone was more effective than zuclopenthixol-depot in improving substance abuse and schizophrenia symptoms in subjects with dual diagnosis.